Published in
American Physiological Society, American Journal of Physiology - Renal Physiology, 2(322), p. F138-F149, 2022
DOI: 10.1152/ajprenal.00104.2021
Links
Tools
Mineralocorticoid receptor blockade with spironolactone has no direct effect on plasma IL-17A and injury markers in urine from kidney transplant patients
Journal article published in 2022 by
Sai Sindhu Thangaraj 
,
Helle Charlotte Thiesson,
Per Svenningsen ,
Jane Stubbe,
Yaseelan Palarasah,
Claus Bistrup ,
Boye L. Jensen ,
Line Aas Mortensen
,
Helle Charlotte Thiesson,
Per Svenningsen ,
Jane Stubbe,
Yaseelan Palarasah,
Claus Bistrup ,
Boye L. Jensen ,
Line Aas Mortensen
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
The mineralocorticoid receptor antagonist spironolactone had no direct anti-inflammatory effects on prohypertensive interleukin-17A or distal nephron epithelial injury markers in kidney transplant recipients.